College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Sci Rep. 2019 Dec 3;9(1):18248. doi: 10.1038/s41598-019-47868-0.
Vascular dementia (VaD) is a complex disorder caused by reduced blood flow in the brain. However, there is no effective pharmacological treatment option available until now. Here, we reported that low-dose levamlodipine besylate could reverse the cognitive impairment in VaD mice model of right unilateral common carotid arteries occlusion (rUCCAO). Oral administration of levamlodipine besylate (0.1 mg/kg) could reduce the latency to find the hidden platform in the MWM test as compared to the vehicle group. Furthermore, vehicle-treated mice revealed reduced phospho-CaMKII (Thr286) levels in the hippocampus, which can be partially restored by levamlodipine besylate (0.1 mg/kg and 0.5 mg/kg) treatment. No significant outcome on microglia and astrocytes were observed following levamlodipine besylate treatment. This data reveal novel findings of the therapeutic potential of low-dose levamlodipine besylate that could considerably enhance the cognitive function in VaD mice.
血管性痴呆（VaD）是一种由大脑血流减少引起的复杂疾病。然而，到目前为止，还没有有效的药物治疗方法。在这里，我们报道了低剂量苯磺酸左旋氨氯地平可以逆转右侧单侧颈总动脉闭塞（rUCCAO）VaD 小鼠模型的认知障碍。与载体组相比，苯磺酸左旋氨氯地平（0.1mg/kg）的口服给药可以减少在 MWM 测试中找到隐藏平台的潜伏期。此外，载体处理的小鼠显示出海马体中磷酸化-CaMKII（Thr286）水平降低，而苯磺酸左旋氨氯地平（0.1mg/kg 和 0.5mg/kg）治疗可以部分恢复该水平。苯磺酸左旋氨氯地平治疗后，小胶质细胞和星形胶质细胞没有明显的变化。这些数据揭示了低剂量苯磺酸左旋氨氯地平治疗的潜在治疗效果，可显著提高 VaD 小鼠的认知功能。
